Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
The Lancet. Oncology.
Times cited: 42
- Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. The New England journal of medicine. 2015 Academic Article GET IT
- Anesthesia management of patients undergoing hyperthermic isolated limb perfusion with melphalan for melanoma treatment: an analysis of 17 cases. Cancers. 2013 Academic Article GET IT